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Introduction {#sec006}
============

Diagnosis and treatment of rifampicin-resistant tuberculosis (RR-TB) remain major public health challenges. Globally in 2018, 484 000 people developed TB that was resistant to rifampicin (the most effective first-line drug) and of these, 78% had multidrug-resistant TB (MDR-TB). The treatment success rate still remains poor (56%) \[[@pone.0237355.ref001]\]. In 2016, World Health Organization (WHO) recommended a shorter regimen (STR) lasting 9 to 12 months for RR/MDR-TB treatment \[[@pone.0237355.ref002]\].

In Guinea, according WHO, there are an estimate 680 incident cases of RR-TB. Diagnosis of RR-TB relies essentially on Xpert MTB/RIF testing in previously treated TB cases and contacts of confirmed RR-TB index cases \[[@pone.0237355.ref003]\]. In 2016, when Guinea was recovering from the devastating Ebola Virus Disease (EVD) outbreak, the introduction of the STR was expected to reduce pressure on both patients and the health system. The STR was reported to result in over 80% programmatic success in nine West and Central African countries using normal-dose moxifloxacin \[[@pone.0237355.ref004]\], even though the Bangladesh STR relied on high-dose gatifloxacin as core drug (the drug driving the efficacy of the regimen) \[[@pone.0237355.ref005]\]. In Guinea, as gatifloxacin was not available anymore \[[@pone.0237355.ref006]\], the STR was built on high-dose moxifloxacin instead of high-dose gatifloxacin as core drug.

No previous study has evaluated the use of a high-dose moxifloxacin STR in programmatic conditions. In the present study, we will describe: 1) the number of patients diagnosed with RR-TB in Guinea and treated between 2016 and 2017. 2) the treatment outcomes and estimate of the effect of using either the longer or shorter treatment regimen.

Methods {#sec007}
=======

Design {#sec008}
------

This is a retrospective cohort study.

Setting {#sec009}
-------

Guinea is a West African country with an estimated population of 12 million. WHO estimates that every year 680 new patients develop resistance to rifampicin TB \[[@pone.0237355.ref001]\].

This study used data from all three sites involved in RR-TB care in the country's capital, Conakry, between 2016 and 2017: Ignace Deen hospital, the TB referral health center Carrière and Tombolia Health Center. Since its implementation in 2011, Xpert MTB/RIF testing has considerably increased to date due to the availability of more GeneXpert machines in the country. The Tombolia Health Center receives support from the Damien Foundation, a Belgian non-governmental organization (NGO) experienced in TB and leprosy's care. This support includes a monthly nutritional package, transport to the health facility fees, and clinical and biological examination free of charge for all MRD/RR-TB patients.

Study population {#sec010}
----------------

All patients diagnosed with rifampicin-resistant pulmonary tuberculosis and treated between 2016 and 2017 in Guinea were included in the study.

Treatment regimens {#sec011}
------------------

Between January and July 2016, only the longer regimen was used. Since August 2016 the STR replaced the longer regimen, while patients already enrolled on the longer regimen continued the same longer regimen. Implemented in 2008, the longer regimen (18--24 months) consisted of 6 months of kanamycin (Km), levofloxacin (Lfx), cycloserin (Cs), prothionamide (Pto) and pyrazinamide (Z), followed by 18 months of Lfx, Pto, Cs and Z (6Km-Lfx-Cs-Pto-Z/18 Lfx-Pto-Cs-Z). The STR regimen, included 4 months of Km, high-dose moxifloxacin (Mfxh), Pto, high-dose isoniazide (Hh), clofazimine (Cfz), ethambutol (E) and Z, followed by 5 months of Mfxh, Cfz, E, and Z (4--6 Km-Mfxh-Pto-Hhd-Cfz-E-Z /5 Mfxh-Cfz-E-Z). The intensive phase can be extended to 6 months when the sputum conversion is not obtained at the end of the 4th or 5th month of treatment \[[@pone.0237355.ref007]\].

Ambulatory care was delivered for patients with a good clinical condition while severely ill patients were hospitalized in the Ignace Deen hospital.

Active drug safety monitoring and management (aDSM) was done but data was not systematically collected in patients treated with the longer regimen.

Data variables, sources and definitions {#sec012}
---------------------------------------

Variables included age, sex, HIV status, MDR-TB clinic, date of treatment start, treatment regimen, and treatment outcomes.

WHO treatment outcomes (cure, treatment completion, death, treatment failure, lost to follow-up and not evaluated) were used \[[@pone.0237355.ref008]\]. Programmatically adverse outcomes were death, treatment failure and lost to follow-up. Programmatically favorable outcomes included cure and treatment completion.

Data collection and analysis {#sec013}
----------------------------

Study data were retrieved from the national Excel® database used to routinely monitor RR-TB treatment and from individual patient files. Data were routinely entered into this database and monthly updated according to patient files. A quality check was performed by National TB Programme and Damien Foundation staff. Patient demographics, clinical characteristics and treatment outcomes were described using counts and proportions.

We calculated medians and interquartile ranges for continuous variables. We used the chi-squared test and the Wilcoxon rank-sum test to compare categorical variables and continuous variables. Univariate and multivariate logistic regression were used to estimate crude and adjusted odds ratios for having a programmatically adverse outcome. The saturated multivariate model was simplified, until all variables in the final model were significant at level 0.05. We used Stata (version 14.2) for analysis.

Ethics {#sec014}
------

The Guinea National Tuberculosis Programme approved conducting the present retrospective study of routinely collected data. Co-authors include National Tuberculosis Programme staff. Informed consent was obtained from all participants before starting treatment. The Institutional Review Board of the Institute of Tropical Medicine Antwerp approved the study protocol. Confidentiality was assured throughout.

Results {#sec015}
=======

In Guinea, in 2016, 131 patients were diagnosed with RR-TB and 108 started treatment. In 2017, 219 patients were diagnosed with RR-TB and 163 started treatment. All 271 patients started on MDR-TB treatment were included in the analysis. Of 271, 75 were started on a longer regimen, and 196 on the STR.

The proportion of patients that were male, HIV positive, and attending a clinic supported by an NGO was similar regardless of the regimen provided. Median age was higher among those treated with a longer regimen (30 years;IQR:24--38) compared to those treated with the shorter regimen (26 years; IQR:21--39) ([Table 1](#pone.0237355.t001){ref-type="table"}).

10.1371/journal.pone.0237355.t001

###### Characteristics among patients who started MDR-TB treatment between 2016 and 2017.

![](pone.0237355.t001){#pone.0237355.t001g}

                                                                        Treatment regimens                               
  ------------------------------------------------------ -------------- -------------------- ---------- ----- ---------- ------
  **Sex**                                                                                                                0.9
  Female                                                 76             21                   28.0       55    28.1       
  Male                                                   195            54                   72.0       141   71.9       
  **Age group (years) (n = 270)**                                                                                        0.1
  0--14                                                  4              2                    2.7        2     1.0        
  15--29                                                 138            46                   61.3       92    46.9       
  30--44                                                 87             19                   25.3       68    34.7       
  \>45                                                   42             8                    10.7       34    17.3       
  Age, median (IQR)                                      28 (23--38)    30                   (24--38)   26    (21--39)   0.02
  **HIV status (n = 270)**                                                                                               0.9
  Negative                                               222            63                   84.0       159   81.1       
  Positive                                               49             12                   16.0       37    18.9       
  **NGO support to the clinic where care is provided**                                       0.7                         
  Yes                                                    102            27                   36.0       75    38.3       
  No                                                     169            48                   64.0       121   61.7       

IQR: interquartile range, n = number.

^a^ Chi-squared test for categorical variables, Wilcoxon rank-sum test for age.

[Table 2](#pone.0237355.t002){ref-type="table"} shows that patients treated with a shorter regimen were more likely to obtain a programmatically favorable outcome (74.0% vs 58.7%, risk difference 15.3% (95%CI:2.6--28.0), p = 0.01). Lost to follow up (LTFU) was higher among those treated with a longer regimen (20.0% vs 8.2%, risk difference 11.8% (95%CI 2.0--21.7), p = 0.006).

10.1371/journal.pone.0237355.t002

###### Treatment outcomes among 271 patients started on MDR-TB treatment in Guinea, 2016 and 2017.

![](pone.0237355.t002){#pone.0237355.t002g}

                                                                      Treatment regimens   
  ------------------------------------------------------------------- -------------------- ------------
  Cured, n(%)                                                         42 (56)              112 (57.1)
  Treatment completed, n(%)                                           2 (2.7)              33 (16.8)
  Died, n(%)                                                          11(14.7)             30(15.3)
  Treatment failure, n(%)                                             5(6.7)               5(2.6)
  Lost to follow-up, n(%)                                             15(20.0)             16(8.2)
  Programmatically favorable[^\$^](#t002fn001){ref-type="table-fn"}   44(58.7)             145(74.0)
  Programmatically adverse                                            31(41.3)             51(26.0)

^\$^ Programmatically adverse outcomes included died, treatment failure, and lost to follow-up, favorable outcomes included cured and treatment completed

[Table 3](#pone.0237355.t003){ref-type="table"} shows that patients on a longer regimen were more than 2 times more likely (aOR: 2.5; 95%CI:1.3,4.7) to have a programmatically adverse outcome. Other factors associated with having a programmatically adverse outcome were: being 45 years or older (aOR: 2.8; 95%CI:1.3,6.2), being HIV positive (aOR:3.3; 95%CI:1.6,6.6), and attendance at a clinic without NGO support (aOR:3.0; 95%:1.6,5.7).

10.1371/journal.pone.0237355.t003

###### Predictors of an programmatically adverse treatment outcome, among 271 patients started on MDR-TB treatment in Guinea, between 2016 and 2017.

![](pone.0237355.t003){#pone.0237355.t003g}

                                                       Unfavorable outcome[^\$^](#t003fn005){ref-type="table-fn"}                                                                                                                          
  ---------------------------------------------- ----- ------------------------------------------------------------ ------ ---------------------------------------------- ----------------- ---------------------------------------------- --------------
  Sex                                                                                                                                                                                       NS                                             
  Female                                         76    26                                                           34.2   1                                                                                                               
  Male                                           195   56                                                           28.7   0.8                                            \[0.44,1.37\]                                                     
  Age groups                                                                                                                                                                                                                               
  \<15                                           4     3                                                            75.0   1                                                                1                                              
  15--30                                         138   31                                                           22.5   10.4[\*](#t003fn001){ref-type="table-fn"}      \[1.04,103.10\]   5.5                                            \[0.4,67.0\]
  30--44                                         87    30                                                           34.5   1.8[\*](#t003fn001){ref-type="table-fn"}       \[1.00,3.30\]     1.6                                            \[0.9,3.2\]
  45-. . .                                       42    18                                                           42.9   2.6[\*](#t003fn001){ref-type="table-fn"}       \[1.25,5.37\]     2.8[\*\*](#t003fn002){ref-type="table-fn"}     \[1.3,6.2\]
  HIV status                                                                                                                                                                                                                               
  Negative                                       222   57                                                           25.7   1                                                                1                                              
  Positive                                       49    25                                                           51     3.0[\*\*\*](#t003fn003){ref-type="table-fn"}   \[1.60,5.70\]     3.3[\*\*\*](#t003fn003){ref-type="table-fn"}   \[1.6,6.6\]
  NGO support to clinic where care is provided                                                                                                                                                                                             
  Yes                                            102   18                                                           17.6   1                                                                1                                              
  No                                             169   64                                                           37.9   2.8[\*\*\*](#t003fn003){ref-type="table-fn"}   \[1.57,5.16\]     3.0[\*\*\*](#t003fn003){ref-type="table-fn"}   \[1.6,5.7\]
  Regimen                                                                                                                                                                                                                                  
  Shorter                                        196   51                                                           26.0   1                                                                1                                              
  Longer                                         75    31                                                           41.3   2.0[\*](#t003fn001){ref-type="table-fn"}       \[1.14,3.51\]     2.5[\*\*](#t003fn002){ref-type="table-fn"}     \[1.3,4.7\]

\* p \< 0.05

\*\* p \< 0.01

\*\*\* p \< 0.001.

NA: not applicable; NS: not significant.

^\$^Programmatically adverse outcomes included died, treatment failure, and lost to follow-up, favorable outcomes included cured and treatment completed.

Discussion {#sec016}
==========

This is the first study comparing a high-dose moxifloxacin STR with a longer MDR-TB treatment regimen in a programmatic setting. Our findings complement those of the STREAM trial, which also compared a high-dose moxifloxacin STR with a longer MDR-TB treatment regimen \[[@pone.0237355.ref009]\]. The STREAM trial showed 79.8% success among those treated with a longer regimen versus 78.8% success among those treated with the STR, and concluded that the STR was non-inferior compared to the longer regimen (1.0% difference, with the 95% CI not exceeding the non-inferiority margin) \[[@pone.0237355.ref009]\]. Our study showed 58.7% vs 74.0% success, with a significant difference of 15.3% (95%CI:2.6--28.0), in favor of the shorter regimen. This difference between both cohorts was mainly explained by a higher proportion of patients reported as lost to follow-up (LTFU) among those treated with a longer regimen (20.0% vs 8.2%) \[[@pone.0237355.ref009], [@pone.0237355.ref010]\]. Our findings are coherent with those from a recent review, which also showed that patients treated with the STR were less likely to be LTFU than those treated with the longer MDR-TB treatment regimen \[[@pone.0237355.ref011]\].

Our findings are important as they facilitate the interpretation of the STREAM results. The STREAM trial, as most trials, was conducted in circumstances that are better controlled than in routine practice. Among STREAM trial patients started on the longer regimen and included in the efficacy analysis, 2.4% (3/124) were LTFU versus 0.4% (1/245) among those treated with the STR \[[@pone.0237355.ref009], [@pone.0237355.ref010]\]. This contrasts with global 2019 WHO update on MDR-TB, showing the reality of National Tuberculosis Programmes, and reporting 21% LTFU among those started on the longer regimen \[[@pone.0237355.ref012]\]. The STREAM findings also contrast with our study findings, showing that 20.0% of those on a longer regimen were LTFU. Of note, the proportion LTFU in our study was very similar to the 21% reported globally \[[@pone.0237355.ref012]\]. We speculate that the STREAM trial setting very likely affected treatment outcomes: patients who would have been LTFU in the real world were disproportionally retained in care in clinical trial conditions, in favor of the longer regimen \[[@pone.0237355.ref009], [@pone.0237355.ref010]\].

WHO 2018 data also show that 15% of patients treated with a longer regimen died, 8% were reported with treatment failure, and only 55% were treated successfully \[[@pone.0237355.ref012]\]. Similarly, in Guinea, of patients treated with a longer regimen 20.0% were LTFU, 14.7% died, and 6.7% had treatment failure, and only 58.7% were treated successfully. We can conclude that treatment outcomes of patients treated with a longer regimen in our setting are very similar to these global figures, reported for the same period.

However, treatment outcomes among patients treated with the shorter regimen were less good than those reported elsewhere in the Western African region \[[@pone.0237355.ref004]\]. In our study 74% were treated successfully, 15.3% died, 8.2% were LTFU, and 2.6% experienced treatment failure. In a study summarizing data from 1006 patients from nine West-African countries (which did not include Guinea) treated with a normal-dose moxifloxacin STR, 81.6% were treated successfully, 7.8% died, 4.8% were LTFU and 5.9% had treatment failure \[[@pone.0237355.ref004]\].

How to explain the lower proportion of programmatic success achieved in Guinea? We speculate that the higher level of mortality and LTFU may be caused by multiple factors, including delayed diagnosis or delayed treatment initiation, lower level of patient support, and/or lower level of quality of clinical care. Even if patients in the study were enrolled on treatment between 2016 and 2017 in the "post-Ebola" period, as a previous showed that the outbreak had little effect on TB programme performance \[[@pone.0237355.ref013]\].

Another predictor of adverse outcomes is initial resistance to fluoroquinolone \[[@pone.0237355.ref005]\] Programmatic success in patients treated with a normal-dose moxifloxacin STR in Swaziland and Uzbekistan was 71% and 70%, respectively. Bacteriologically adverse outcomes, either failure or relapse, were as frequent as 15% and 16.7% \[[@pone.0237355.ref014]\]. Initial resistance to drugs used in the STR, especially the fluoroquinolone, may explain these poor results \[[@pone.0237355.ref005], [@pone.0237355.ref014]\]. Even though initial resistance to fluoroquinolone was not tested systematically, we speculate that initial resistance does not explain the outcomes shown in Guinea, as only 2.6% of patients were reported with treatment failure, much lower than in the above mentioned settings with a high prevalence of fluoroquinolone resistance.

The proportion of patients with treatment failure was lower in the Guinea cohort than in the cohort showing data from nine African countries, where normal-dose moxifloxacin was used. The effect of moxifloxacin on microbiological kill is known to be dose-dependent \[[@pone.0237355.ref015]\]. But more important than the dosing of moxifloxacin, recent evidence shows that the choice of fluoroquinolone affects treatment outcomes \[[@pone.0237355.ref016]\]. In cohorts using a gatifloxacin-based STR, programmatic success ranged between 84.5% and 89%, with 1.4% (7/515) and 0.7% (1/150) treatment failure in Bangladesh and in Cameroon, respectively \[[@pone.0237355.ref005], [@pone.0237355.ref017], [@pone.0237355.ref018]\]. Gatifloxacin-based STR perform better than moxifloxacin-based STR in terms of bacteriological outcomes \[[@pone.0237355.ref016]\]. A recent study showed that a moxifloxacin-based STR had a 8.4-fold times larger odds of having an adverse bacteriological outcome. Moreover, none of the patients on a gatifloxacin-based regimen developed resistance to fluoroquinolone, while 4 of 228 patients with initially fluoroquinolone- susceptible TB developed resistance \[[@pone.0237355.ref016]\].

Our study has some important limitations. Data on conditions that could affect outcomes, such as alcoholism, diabetes and chronic obstructive pulmonary disease, were not systematically collected, and therefore not included in the analysis. Phenotypic or genotypic drug susceptibility testing was not available to exhaustively determine the initial resistance profile; hence the effect of initial resistance on treatment response was not assessed. We did also not present data on the safety of the longer or shorter regimen, as these were not collected systematically. However, the STREAM trial studied the same regimens and showed that both regimens resulted in a similar frequency of adverse events \[[@pone.0237355.ref009]\]. Another limitation is the enrollment of all patients on the longer regimen in 2016 while patients treated with the STR were enrolled in both 2016 and 2017. On the other hand, given the long duration of the longer regimen, the treatment period of both cohorts overlapped as patients on the longer regimen were treated until 2018, making systematic bias less likely. Moreover, the MDR-TB programme was stable between 2016 and 2018, relying on Xpert MTB/RIF for RR-TB diagnosis, and the treatment regimens described in this manuscript. Finally, inherent to the design of the study, patients enrolled in the longer and shorter regimen may not have been entirely comparable. On the other hand, measured baseline characteristics did not identify relevant differences between both cohorts. Another strength of the study is its exhaustive national sample and the use of routinely collected data. Hence, our findings are generalizable for the Guinean setting.

Conclusion {#sec017}
==========

In Guinea, programmatic success was higher when patients were treated with a high-dose moxifloxacin-based STR, when compared with a longer MDR-TB treatment regimen. However, outcomes of the STR cohort were less good than those reported elsewhere in the Western African region. Our findings, showing the reality of the National Tuberculosis Programme in Guinea, complement findings of the STREAM trial, the only other study that evaluated a high-dose moxifloxacin-based STR against a longer regimen.
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Souleymane Hassane Harouna et al analyzed the response of RR TB patients for various treatment regimen and compared the efficacy of short tern regimen with long term treatment outcome .

This is sound clinical study which address various issues related to the resistance / sensitivity of the patients toward anti TB drug regimens.

I have following concern which is related to the microbiological aspect of the study and feel that addressing this would enhanced the quality of the study multi-folds

RESPONSE: Many thanks for the constructive feedback.

1\. The author should clarify the exclusion criteria for the patients which they have selected , How many patients had Aspergillosis, COPD and diabetes because these traits can influence the outcome of the treatment and this is believed to be responsible for the adverse outcome during long term treatment regimen.

RESPONSE: This study describes the routine management of multidrug resistant tuberculosis in Guinea. Thus all patients treated in the study period were included as said in the method section. None of these patients had Aspergillosis.

Indeed, COPD and diabetes may affect the outcome. Unfortunately, these data were not systematically collected for all patients, hence not included in the analysis. We therefore expanded the limitations section in the discussion as follows: "Data on conditions that could affect the outcomes, such as alcoholism, diabetes and chronic obstructive pulmonary disease, were not systematically collected, and therefore not included in the analysis."(line 238)

2\. I would advice author to select 5 patients in both STR and LTR and analyze whole genome analysis of bacterial genes because i feel that mycobacterial devR and dosR responsive element may also provide a microbiological correlation with respect to the response of the patients

RESPONSE: This retrospective study analyses data collected in routine practice. As our lab is not able to perform whole genome sequencing (WGS), WGS data (or other tests to exhaustively determine the resistance profile) were not available. This point also will be added as a limitation: "Phenotypic or genotypic drug susceptibility testing was not available to exhaustively determine the initial resistance profile; hence the effect of initial resistance on treatment response was not assessed" Line 240

3\. Considering the resistance of patients for LTR , whether inclusion of Rapamycin or bedaquiline can change the response in LTR group.

RESPONSE: Indeed, for patients with resistance to drugs included in the LTR or in general patients who had failed to either a LTR or STR, a bedaquiline (Bdq) based regimen has to be considered. The current MDR-TB guidelines even recommends to replace the injectable by Bdq in the STR and we are planning to assess this strategy. However, during the period of this study, Bdq was not available.

Rapamycin does not exist in our programme and is not also mentioned in the 2020 WHO recommendation on drug-resistant tuberculosis treatment.

4\. Immunological nitch is linked to latency / dormancy related phenotype in TB so from that analyzing few patients with foamy macrophage, MDSC , Treg along with HLA-G pattern may add to the immune mediated mechanism responsible for adverse response in LTR groups

RESPONSE: We assumed that "MDSC" stands for "myeloid-derived suppressor cells". We are not aware of studies describing how much immunological factors explain the difference in terms of treatment response between longer and shorter treatment regimens. The aims of our study did not include this component. Moreover, the difference in terms of having a programmatically adverse outcome (either died, lost to follow-up, or treatment failure) in favor of the shorter regimen was explained by the higher proportion of patients lost to follow-up during treatment with the longer regimen. We believe that LTFU is explained by the tolerability of the treatment regimen, considering that most second-line TB drugs provoke adverse events.

Reviewer \#2: Comments:

Harouna et al. written about the treatment outcome for shorter treatment regimen and longer regimen categories with modified treatment in existing treatment regimen. Data proved the treatment utility and recommendations in present scenario for TB programme successfully progresses worldwide. Following are some suggestions which can make the manuscript stronger and beneficial for the readers:

RESPONSE: Many thanks for the feedback which improved the clarity of the manuscript

Abstract:

• Abbreviation of rifampicin resistance (RR) should come upon first appearance in the text.

RESPONSE: Ok, it has been inserted in the abstract.

Introduction:

• Introduction should modify because author had discussed previous trail related to the present study. That would be a part of discussion only. Line no. 60 to 72

RESPONSE: OK, these phrases were deleted.

• Reference No. 1 should be updated with recent one.

RESPONSE: Ok, it has been done. Now we refer to the 2019 WHO report, presenting data for 2018.

• It's little bit inequality and confusing regarding the sentences for the dose of MFX used in the study. Line no. 57 (This study used normal-dose moxifloxacin.) indicated normal dose while, in Line no. 60 (In Guinea, the STR relied on high-dose moxifloxacin instead) high dose MFX is mentioned.

RESPONSE: Normal-dose moxifloxacin was used in the nine West and Central African countries study whereas the high-dose moxifloxacin was used in the current study.

• In first objective, author had mentioned about the diagnosis and number of RR-TB. In that view, author should write few points about the prevalence and diagnostics modalities used in his country.

RESPONSE: OK, see lines (55-57)

Method: It observed that author/s ware collected the data very precisely. However, required some information to improve manuscript like:

• Delete "longer" (line no. 99, continued the same longer regimen.).

RESPONSE: OK, it is done in the text.

• Add references regarding the doses and drugs for STR and longer regimen. (Line no. 97-106).

RESPONSE: OK

• Author should point out the type (pulmonary or extra-pulmonary) of tuberculosis among patient requited for this study.

RESPONSE: OK, see line no 96

• In patient history, alcoholism and smoker status of patient as well as house hold contact should be noted if possible. Because these habits are strongly associated with treatments which leads to recurrence.

RESPONSE: This observation is very relevant but unfortunately these data were not systematically recorded. We expanded the limitations section in the discussion as follows: "Data on conditions that could affect the outcomes, such as alcoholism, diabetes and chronic obstructive pulmonary disease, were not systematically collected, and therefore not included in the analysis."(line 238)

Discussion:

• Provide reference for these sentences. Like:

"The STREAM trial showed 79.8% success among those treated with a...."

RESPONSE: Ok see line 178

"We speculate that the STREAM trial setting very likely affected treatment.." We added references: RESPONSE: "Of note, the proportion LTFU in our study was very similar to the 21% reported globally (12). We speculate that the STREAM trial setting very likely affected treatment outcomes: patients who would have been LTFU in the real world were disproportionally retained in care in clinical trial conditions, in favor of the longer regimen (9)." Line 190

"However, treatment outcomes among patients treated with the shorter regimen .."

RESPONSE: We added a reference: "However, treatment outcomes among patients treated with the shorter regimen were less good than those reported elsewhere in the Western African region (4)." Line 204

"But more important than the dosing of moxifloxacin, recent evidence shows that the choice of fluoroquinolone.."

RESPONSE: Ok see line 230 "But more important than the dosing of moxifloxacin, recent evidence shows that the choice of fluoroquinolone affects treatment outcomes (16)."

• Author should modify the sentence "Another predictor of treatment success is initial resistance to fluoroquinolone", "Bacteriologically adverse outcomes, either failure or relapse, were as frequent as 15% and 16.7%".

RESPONSE: Ok, we modified to "Another predictor of adverse outcomes is initial resistance to fluoroquinolone" see line 217

• Authors are advised to cite some recent studies found relevant to the present study.

RESPONSE: We refer to a recently published review. Line 181: "Our findings are coherent with those from a recent review, which also showed that patients treated with the STR were less likely to be LTFU than those treated with the longer MDR-TB treatment regimen (reference 11)."

Conclusion: Authors are advised to reframe the sentence (Although better than outcomes from patients.....)

RESPONSE: Ok see lines 257-262: "In Guinea, programmatic success was higher when patients were treated with a high-dose moxifloxacin-based STR, when compared with a longer MDR-TB treatment regimen. However, outcomes of the STR cohort were less good than those reported elsewhere in the Western African region. Our findings, showing the reality of the National Tuberculosis Programme in Guinea, complement findings of the STREAM trial, the only other study that evaluated a high-dose moxifloxacin-based STR against a longer regimen."
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Dear Dr. Hassane-Harouna,

We're pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you'll receive an e-mail detailing the required amendments. When these have been addressed, you'll receive a formal acceptance letter and your manuscript will be scheduled for publication.
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If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they'll be preparing press materials, please inform our press team as soon as possible \-- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact <onepress@plos.org>.

Kind regards,

Hasnain Seyed Ehtesham

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

I have gone through this revised manuscript and also the Author response to the comments of the Reviewers. Authors have made required changes in the manuscript and added references wherever required. Authors have expanded the limitation section in the discussion part. As suggested by one of the reviewer Authors have also added few points about the prevalence and diagnostics modalities used in his country in line no.55-57. The authors have satisfactorily addressed all the comments made by the reviewers and added all required information, and have revised the manuscript accordingly. I recommend this manuscript for publication.

Reviewers\' comments:

10.1371/journal.pone.0237355.r004

Acceptance letter

Ehtesham

Hasnain Seyed

Academic Editor

© 2020 Hasnain Seyed Ehtesham

2020

Hasnain Seyed Ehtesham

This is an open access article distributed under the terms of the

Creative Commons Attribution License

, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

30 Jul 2020

PONE-D-20-12232R1

Better programmatic outcome with the shorter regimen for the treatment of multidrug-resistant tuberculosis (MDR-TB) in Guinea: a retrospective cohort study

Dear Dr. HASSANE-HAROUNA:

I\'m pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they\'ll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact <onepress@plos.org>.

If we can help with anything else, please email us at <plosone@plos.org>.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Prof Hasnain Seyed Ehtesham

Academic Editor

PLOS ONE

[^1]: **Competing Interests:**The authors have declared that no competing interests exist.

[^2]: ‡ These authors are joint first authors.
